Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey
Abstract Background Serosurveys help to ascertain burden of infection. Prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys in New York City (NYC) used nonrandom samples. During June–October 2020, the NYC Health Department conducted a population-based survey estimating SARS...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2021-07, Vol.224 (2), p.188-195 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 2 |
| container_start_page | 188 |
| container_title | The Journal of infectious diseases |
| container_volume | 224 |
| creator | Parrott, Jannae C Maleki, Ariana N Vassor, Valerie E Osahan, Sukhminder Hsin, Yusyin Sanderson, Michael Fernandez, Steven Levanon Seligson, Amber Hughes, Scott Wu, Jing DeVito, Andrea K LaVoie, Stephen P Rakeman, Jennifer L Gould, L Hannah Alroy, Karen A |
| description | Abstract
Background
Serosurveys help to ascertain burden of infection. Prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys in New York City (NYC) used nonrandom samples. During June–October 2020, the NYC Health Department conducted a population-based survey estimating SARS-CoV-2 antibody prevalence in NYC adults.
Methods
Participants were recruited from the NYC 2020 Community Health Survey. We estimated citywide and stratified antibody prevalence using a hybrid design: serum tested with the DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG assay and self-reported antibody test results were used together. We estimated univariate frequencies and 95% confidence intervals (CI), accounting for complex survey design. Two-sided P values ≤ .05 were statistically significant.
Results
There were 1074 respondents; 497 provided blood and 577 provided only a self-reported antibody test result. Weighted prevalence was 24.3% overall (95% CI, 20.7%–28.3%). Latino (30.7%; 95% CI, 24.1%–38.2%; P |
| doi_str_mv | 10.1093/infdis/jiab296 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8244597</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiab296</oup_id><sourcerecordid>2572577144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-5b4635bb38afda0f60edc575957dbda7b663dc06194d04ca4dc7cb215d2ff2fa3</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhYMoTk_r1nXAjcLUTCpJpTouhLLxl8EZbBVchfxqeqqTNqm09M538A19EiPdCLoRLtzF_c7h3nsAeNCi8xZxcuGDMz5frL1UmLNbYNZ2pG8Ya8ltMEMI46ZdcH4CTnNeI4QoYf1dcEIoWjCOyQzcXCe7k6MN2sLo4Gp4t2qW8WOD4RAmr6LxNkMf4Fv7DX6K6QYu_bSHgynjlM_gmxLsz-8_rvQUlU0QI4yewAFex20Z5eRjaJ7JbA1clbSz-3vgjpNjtvePfQ4-vHj-fvmqubx6-Xo5XDaaYj41naKMdEqRhXRGIseQNbrrO971RhnZK8aI0Yi1nBpEtaRG91rhtjPYOewkmYOnB99tUZuqtWFKchTb5Dcy7UWUXvw9Cf6L-Bx3YoEp7XhfDR4dDVL8WmyexMZnbcdRBhtLFrj-mBHE66_n4OE_6DqWFOp5lepr9S2llTo_UDrFnJN1f5ZpkfidozjkKI45VsHjgyCW7f_YX1KvoGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572577144</pqid></control><display><type>article</type><title>Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Parrott, Jannae C ; Maleki, Ariana N ; Vassor, Valerie E ; Osahan, Sukhminder ; Hsin, Yusyin ; Sanderson, Michael ; Fernandez, Steven ; Levanon Seligson, Amber ; Hughes, Scott ; Wu, Jing ; DeVito, Andrea K ; LaVoie, Stephen P ; Rakeman, Jennifer L ; Gould, L Hannah ; Alroy, Karen A</creator><creatorcontrib>Parrott, Jannae C ; Maleki, Ariana N ; Vassor, Valerie E ; Osahan, Sukhminder ; Hsin, Yusyin ; Sanderson, Michael ; Fernandez, Steven ; Levanon Seligson, Amber ; Hughes, Scott ; Wu, Jing ; DeVito, Andrea K ; LaVoie, Stephen P ; Rakeman, Jennifer L ; Gould, L Hannah ; Alroy, Karen A</creatorcontrib><description>Abstract
Background
Serosurveys help to ascertain burden of infection. Prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys in New York City (NYC) used nonrandom samples. During June–October 2020, the NYC Health Department conducted a population-based survey estimating SARS-CoV-2 antibody prevalence in NYC adults.
Methods
Participants were recruited from the NYC 2020 Community Health Survey. We estimated citywide and stratified antibody prevalence using a hybrid design: serum tested with the DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG assay and self-reported antibody test results were used together. We estimated univariate frequencies and 95% confidence intervals (CI), accounting for complex survey design. Two-sided P values ≤ .05 were statistically significant.
Results
There were 1074 respondents; 497 provided blood and 577 provided only a self-reported antibody test result. Weighted prevalence was 24.3% overall (95% CI, 20.7%–28.3%). Latino (30.7%; 95% CI, 24.1%–38.2%; P < .01) and black (30.7%; 95% CI, 21.9%–41.2%; P = .02) respondents had a higher weighted prevalence compared with white respondents (17.4%; 95% CI, 12.5%–23.7%).
Conclusions
By October 2020, nearly 1 in 3 black and 1 in 3 Latino NYC adults had SARS-CoV-2 antibodies, highlighting unequal impacts of the coronavirus disease 2019 (COVID-19) pandemic on black and Latino NYC adults.
We estimate SARS-CoV-2 antibody prevalence among NYC residential adults June–October 2020 with serosurvey and self-reported data, enabling reliable estimates citywide and by demographic and socioeconomic groups. This population-based survey offers important confirmation of prior convenience-based serosurveys in NYC.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiab296</identifier><identifier>PMID: 34086923</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antibodies ; Coronaviruses ; COVID-19 ; Immunoglobulin G ; Major ; Pandemics ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis</subject><ispartof>The Journal of infectious diseases, 2021-07, Vol.224 (2), p.188-195</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2021. 2021</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2021.</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2021. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-5b4635bb38afda0f60edc575957dbda7b663dc06194d04ca4dc7cb215d2ff2fa3</citedby><cites>FETCH-LOGICAL-c429t-5b4635bb38afda0f60edc575957dbda7b663dc06194d04ca4dc7cb215d2ff2fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids></links><search><creatorcontrib>Parrott, Jannae C</creatorcontrib><creatorcontrib>Maleki, Ariana N</creatorcontrib><creatorcontrib>Vassor, Valerie E</creatorcontrib><creatorcontrib>Osahan, Sukhminder</creatorcontrib><creatorcontrib>Hsin, Yusyin</creatorcontrib><creatorcontrib>Sanderson, Michael</creatorcontrib><creatorcontrib>Fernandez, Steven</creatorcontrib><creatorcontrib>Levanon Seligson, Amber</creatorcontrib><creatorcontrib>Hughes, Scott</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>DeVito, Andrea K</creatorcontrib><creatorcontrib>LaVoie, Stephen P</creatorcontrib><creatorcontrib>Rakeman, Jennifer L</creatorcontrib><creatorcontrib>Gould, L Hannah</creatorcontrib><creatorcontrib>Alroy, Karen A</creatorcontrib><title>Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey</title><title>The Journal of infectious diseases</title><description>Abstract
Background
Serosurveys help to ascertain burden of infection. Prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys in New York City (NYC) used nonrandom samples. During June–October 2020, the NYC Health Department conducted a population-based survey estimating SARS-CoV-2 antibody prevalence in NYC adults.
Methods
Participants were recruited from the NYC 2020 Community Health Survey. We estimated citywide and stratified antibody prevalence using a hybrid design: serum tested with the DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG assay and self-reported antibody test results were used together. We estimated univariate frequencies and 95% confidence intervals (CI), accounting for complex survey design. Two-sided P values ≤ .05 were statistically significant.
Results
There were 1074 respondents; 497 provided blood and 577 provided only a self-reported antibody test result. Weighted prevalence was 24.3% overall (95% CI, 20.7%–28.3%). Latino (30.7%; 95% CI, 24.1%–38.2%; P < .01) and black (30.7%; 95% CI, 21.9%–41.2%; P = .02) respondents had a higher weighted prevalence compared with white respondents (17.4%; 95% CI, 12.5%–23.7%).
Conclusions
By October 2020, nearly 1 in 3 black and 1 in 3 Latino NYC adults had SARS-CoV-2 antibodies, highlighting unequal impacts of the coronavirus disease 2019 (COVID-19) pandemic on black and Latino NYC adults.
We estimate SARS-CoV-2 antibody prevalence among NYC residential adults June–October 2020 with serosurvey and self-reported data, enabling reliable estimates citywide and by demographic and socioeconomic groups. This population-based survey offers important confirmation of prior convenience-based serosurveys in NYC.</description><subject>Antibodies</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Immunoglobulin G</subject><subject>Major</subject><subject>Pandemics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkc2KFDEUhYMoTk_r1nXAjcLUTCpJpTouhLLxl8EZbBVchfxqeqqTNqm09M538A19EiPdCLoRLtzF_c7h3nsAeNCi8xZxcuGDMz5frL1UmLNbYNZ2pG8Ya8ltMEMI46ZdcH4CTnNeI4QoYf1dcEIoWjCOyQzcXCe7k6MN2sLo4Gp4t2qW8WOD4RAmr6LxNkMf4Fv7DX6K6QYu_bSHgynjlM_gmxLsz-8_rvQUlU0QI4yewAFex20Z5eRjaJ7JbA1clbSz-3vgjpNjtvePfQ4-vHj-fvmqubx6-Xo5XDaaYj41naKMdEqRhXRGIseQNbrrO971RhnZK8aI0Yi1nBpEtaRG91rhtjPYOewkmYOnB99tUZuqtWFKchTb5Dcy7UWUXvw9Cf6L-Bx3YoEp7XhfDR4dDVL8WmyexMZnbcdRBhtLFrj-mBHE66_n4OE_6DqWFOp5lepr9S2llTo_UDrFnJN1f5ZpkfidozjkKI45VsHjgyCW7f_YX1KvoGQ</recordid><startdate>20210715</startdate><enddate>20210715</enddate><creator>Parrott, Jannae C</creator><creator>Maleki, Ariana N</creator><creator>Vassor, Valerie E</creator><creator>Osahan, Sukhminder</creator><creator>Hsin, Yusyin</creator><creator>Sanderson, Michael</creator><creator>Fernandez, Steven</creator><creator>Levanon Seligson, Amber</creator><creator>Hughes, Scott</creator><creator>Wu, Jing</creator><creator>DeVito, Andrea K</creator><creator>LaVoie, Stephen P</creator><creator>Rakeman, Jennifer L</creator><creator>Gould, L Hannah</creator><creator>Alroy, Karen A</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210715</creationdate><title>Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey</title><author>Parrott, Jannae C ; Maleki, Ariana N ; Vassor, Valerie E ; Osahan, Sukhminder ; Hsin, Yusyin ; Sanderson, Michael ; Fernandez, Steven ; Levanon Seligson, Amber ; Hughes, Scott ; Wu, Jing ; DeVito, Andrea K ; LaVoie, Stephen P ; Rakeman, Jennifer L ; Gould, L Hannah ; Alroy, Karen A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-5b4635bb38afda0f60edc575957dbda7b663dc06194d04ca4dc7cb215d2ff2fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Immunoglobulin G</topic><topic>Major</topic><topic>Pandemics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parrott, Jannae C</creatorcontrib><creatorcontrib>Maleki, Ariana N</creatorcontrib><creatorcontrib>Vassor, Valerie E</creatorcontrib><creatorcontrib>Osahan, Sukhminder</creatorcontrib><creatorcontrib>Hsin, Yusyin</creatorcontrib><creatorcontrib>Sanderson, Michael</creatorcontrib><creatorcontrib>Fernandez, Steven</creatorcontrib><creatorcontrib>Levanon Seligson, Amber</creatorcontrib><creatorcontrib>Hughes, Scott</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>DeVito, Andrea K</creatorcontrib><creatorcontrib>LaVoie, Stephen P</creatorcontrib><creatorcontrib>Rakeman, Jennifer L</creatorcontrib><creatorcontrib>Gould, L Hannah</creatorcontrib><creatorcontrib>Alroy, Karen A</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parrott, Jannae C</au><au>Maleki, Ariana N</au><au>Vassor, Valerie E</au><au>Osahan, Sukhminder</au><au>Hsin, Yusyin</au><au>Sanderson, Michael</au><au>Fernandez, Steven</au><au>Levanon Seligson, Amber</au><au>Hughes, Scott</au><au>Wu, Jing</au><au>DeVito, Andrea K</au><au>LaVoie, Stephen P</au><au>Rakeman, Jennifer L</au><au>Gould, L Hannah</au><au>Alroy, Karen A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey</atitle><jtitle>The Journal of infectious diseases</jtitle><date>2021-07-15</date><risdate>2021</risdate><volume>224</volume><issue>2</issue><spage>188</spage><epage>195</epage><pages>188-195</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
Background
Serosurveys help to ascertain burden of infection. Prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys in New York City (NYC) used nonrandom samples. During June–October 2020, the NYC Health Department conducted a population-based survey estimating SARS-CoV-2 antibody prevalence in NYC adults.
Methods
Participants were recruited from the NYC 2020 Community Health Survey. We estimated citywide and stratified antibody prevalence using a hybrid design: serum tested with the DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG assay and self-reported antibody test results were used together. We estimated univariate frequencies and 95% confidence intervals (CI), accounting for complex survey design. Two-sided P values ≤ .05 were statistically significant.
Results
There were 1074 respondents; 497 provided blood and 577 provided only a self-reported antibody test result. Weighted prevalence was 24.3% overall (95% CI, 20.7%–28.3%). Latino (30.7%; 95% CI, 24.1%–38.2%; P < .01) and black (30.7%; 95% CI, 21.9%–41.2%; P = .02) respondents had a higher weighted prevalence compared with white respondents (17.4%; 95% CI, 12.5%–23.7%).
Conclusions
By October 2020, nearly 1 in 3 black and 1 in 3 Latino NYC adults had SARS-CoV-2 antibodies, highlighting unequal impacts of the coronavirus disease 2019 (COVID-19) pandemic on black and Latino NYC adults.
We estimate SARS-CoV-2 antibody prevalence among NYC residential adults June–October 2020 with serosurvey and self-reported data, enabling reliable estimates citywide and by demographic and socioeconomic groups. This population-based survey offers important confirmation of prior convenience-based serosurveys in NYC.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34086923</pmid><doi>10.1093/infdis/jiab296</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2021-07, Vol.224 (2), p.188-195 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8244597 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antibodies Coronaviruses COVID-19 Immunoglobulin G Major Pandemics Severe acute respiratory syndrome coronavirus 2 Statistical analysis |
| title | Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T05%3A42%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20SARS-CoV-2%20Antibodies%20in%20New%20York%20City%20Adults,%20June%E2%80%93October%202020:%20A%20Population-Based%20Survey&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Parrott,%20Jannae%20C&rft.date=2021-07-15&rft.volume=224&rft.issue=2&rft.spage=188&rft.epage=195&rft.pages=188-195&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiab296&rft_dat=%3Cproquest_pubme%3E2572577144%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572577144&rft_id=info:pmid/34086923&rft_oup_id=10.1093/infdis/jiab296&rfr_iscdi=true |